Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 54 out of 100. Caregiving

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Amyloid-β (Aβ) pathology is one of the earliest detectable brain changes in Alzheimer's disease (AD) pathogenesis. The overall load and spatial distribution of brain Aβ can be determined in vivo using positron emission tomography (PET), for which three fluorine-18 labelled radiotracers have been approved for clinical use. In clinical practice, trained readers will categorise scans as either Aβ positive or negative, based on visual inspection. Diagnostic decisions are often based on these reads and patient selection for clinical trials is increasingly guided by amyloid status. However, tracer deposition in the grey matter as a function of amyloid load is an inherently continuous process, which is not sufficiently appreciated through binary cut-offs alone. State-of-the-art methods for amyloid PET quantification can generate tracer-independent measures of Aβ burden. Recent research has shown the ability of these quantitative measures to highlight pathological changes at the earliest stages of the AD continuum and generate more sensitive thresholds, as well as improving diagnostic confidence around established binary cut-offs. With the recent FDA approval of aducanumab and more candidate drugs on the horizon, early identification of amyloid burden using quantitative measures is critical for enrolling appropriate subjects to help establish the optimal window for therapeutic intervention and secondary prevention. In addition, quantitative amyloid measurements are used for treatment response monitoring in clinical trials. In clinical settings, large multi-centre studies have shown that amyloid PET results change both diagnosis and patient management and that quantification can accurately predict rates of cognitive decline. Whether these changes in management reflect an improvement in clinical outcomes is yet to be determined and further validation work is required to establish the utility of quantification for supporting treatment endpoint decisions. In this state-of-the-art review, several tools and measures available for amyloid PET quantification are summarised and discussed. Use of these methods is growing both clinically and in the research domain. Concurrently, there is a duty of care to the wider dementia community to increase visibility and understanding of these methods.

What this study adds

Evidence grade: Low

This is a narrative review. Amyloid PET scans are usually read by eye as simply "positive" or "negative", but this review argues that amyloid builds up continuously and that binary cut-offs alone do not capture it well. It reports that quantitative, tracer-independent measures can flag changes at the earliest stages of Alzheimer's, sharpen diagnostic confidence, and, according to large multi-centre studies it cites, predict rates of cognitive decline.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Pemberton, H. G., Collij, L. E., Heeman, F., Bollack, A., Shekari, M., Salvadó, G., et al. (2022). Quantification of amyloid PET for future clinical use: a state-of-the-art review. European journal of nuclear medicine and molecular imaging. https://doi.org/10.1007/s00259-022-05784-y

Vancouver

Pemberton HG, Collij LE, Heeman F, Bollack A, Shekari M, Salvadó G, et al. Quantification of amyloid PET for future clinical use: a state-of-the-art review. European journal of nuclear medicine and molecular imaging. 2022. doi:10.1007/s00259-022-05784-y. PMID: 35389071.

BibTeX

@article{pemberton2022-35389071,
  author  = {Pemberton, H. G. and Collij, L. E. and Heeman, F. and Bollack, A. and Shekari, M. and Salvadó, G. and Alves, I. L. and Garcia, D. V. and others},
  title   = {{Quantification of amyloid PET for future clinical use: a state-of-the-art review}},
  journal = {European journal of nuclear medicine and molecular imaging},
  year    = {2022},
  doi     = {10.1007/s00259-022-05784-y},
  pmid    = {35389071},
  url     = {https://doi.org/10.1007/s00259-022-05784-y}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

Amyloid PET scans are usually read by eye as simply "positive" or "negative", but this review argues that amyloid builds up continuously and that binary cut-offs alone do not capture it well. It reports that quantitative, tracer-independent measures can flag changes at the earliest stages of Alzheimer's, sharpen diagnostic confidence, and, according to large multi-centre studies it cites, predict rates of cognitive decline. It is a review about diagnosis and choosing who enters trials; it does not test any treatment.

Study details

How this study scored 54/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 3 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 5 of 7; Citations per year 4 of 5; Impact for its field and year 5 of 6; Cited by studies here 3 of 6; Still being cited 3 of 4; Senior author's track record 2 of 4; Institution's track record 2 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 54 of 100.54 of 100 points earned46 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (European journal of nuclear medicine and molecular imaging)
Journal's citation record 2 / 4 European Journal of Nuclear Medicine and Molecular Imaging: journal h-index 224 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 3 / 5 2022 — within 6 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 5 / 7 Cited 221 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 36.8 citations a year over 6 year(s) since 2022
Impact for its field and year 5 / 6 Cited 24.1× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 3 / 6 Cited by 25 other studies in this library
Still being cited 3 / 4 Cited 191 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Gill Farrar: h-index 30 (OpenAlex, whole career)
Institution's track record 2 / 3 University College London: institution h-index 2,029 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 14 institution(s) in 5 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 35389071)
Free to read 2 / 2 Free to read
Total 54 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 53.

Later studies that cite this one

25 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Caregiving from nearby years

Also tagged “machine”

834 studies in the library carry the topic tag “machine”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 834 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Caregiving

See all studies in Caregiving →